skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Serum anti-Müllerian hormone as a predictive marker of polycystic ovarian syndrome

Original Research

(1641) Views  (439) Full article downloads

Authors: Parco S, Novelli C, Vascotto F, Princi T


Video abstract presented by Dr Sergio Parco
Views: 69

Published Date November 2011 Volume 2011:4 Pages 759 - 763
DOI: http://dx.doi.org/10.2147/IJGM.S25639

Sergio Parco1, Caterina Novelli2, Fulvia Vascotto1, Tanja Princi2
1Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy; 2Department of Life Sciences, University of Trieste, Garofolo, Trieste, Italy

Background: The anti-Müllerian hormone (AMH) is a dimeric protein secreted by the female ovaries and has two fundamental roles in follicle genesis. It delays the entrance of the primordial follicle into the pool of follicles in growth and diminishes the sensitivity of the ovarian follicle towards follicle-stimulating hormone (FSH). The purpose of this work was to study the AMH (nv 2.0–6.8 ng/mL) as a marker during assisted reproductive technology (ART), in order to identify cases of infertility due to polycystic ovarian syndrome (PCOS). This syndrome affects 10% of women with infertility problems, and a new biological marker could be useful to general practitioners of internal medicine to help generate the suspicion of PCOS so that they can refer the patient to the gynecologist for confirmation.
Methods: This study enrolled 236 patients aged 26–46 years undergoing assisted reproductive technology at the Institute for Maternal and Child Health, Trieste, Italy. On the third day of the ovarian cycle, the patients were given doses of AMH, FSH, and luteinizing hormone (LH, in cases of AMH > 2.0–6.8 ng/mL). A control pelvic ultrasound was also carried out.
Results: We identified 57 patients who were starting in vitro fertilization or embryo transfer with AMH values within the normal range (3.64 ± 1.51 ng/mL), 77 with values below normal (1.38 ± 0.32 ng/mL), and 96 cases with undetectable values of AMH. Six patients had very high AMH levels (10.0 ± 2.28 ng/mL) and, of these, five were found to have PCOS on pelvic ultrasound examination (P < 0.05). We also found inverse correlations between AMH levels and age (r = –0.52) and between AMH and FSH levels (r = –0.32).
Conclusion: In clinical practice it is common to encounter patients who turn to medicine in search of a cure for female infertility. In our experience, AMH two or three times the normal amount (10 ± 2.28 ng/mL), is a good indication of PCOS and infertility.

Keywords: anti-Müllerian hormone, serum level, follicle development, polycystic ovarian syndrome, predictive marker





 

Other articles by Dr Sergio Parco



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Risk of “silent stroke” in patients older than 60 years: risk assessment and clinical perspectives
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Selenium–vitamin E supplementation in infertile men: effects on semen parameters and pregnancy rate
Treatment options for polycystic ovary syndrome
Insulin action in adipose tissue in type 1 diabetes
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Erratum
Assessment of coronary heart diseases in diabetics in al-Madinah al-Munawarah
Correlation between aromatase expression in the eutopic endometrium of symptomatic patients and the presence of endometriosis
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University